Day Jonathan, Fletcher Amanda N, Motsay Morgan, Manchester Maggie, Arthur Mark, Zhang Zijun, Schon Lew C
Department of Orthopaedic Surgery, MedStar Union Memorial Hospital, Baltimore, Maryland.
Institute for Foot and Ankle Reconstruction, Mercy Medical Center, Baltimore, Maryland.
J Bone Joint Surg Am. 2025 Apr 29;107(12):e61. doi: 10.2106/JBJS.24.00983.
While most total ankle arthroplasty (TAA) procedures utilize an anterior approach for implantation, the Zimmer Biomet Trabecular Metal implant is unique in that it utilizes a lateral transfibular approach. We present the largest mid-term study to date to analyze the implant survivorship and clinical and radiographic outcomes of transfibular TAA at a minimum 5-year follow-up.
We retrospectively identified and evaluated 130 ankles (122 patients; mean age, 60.8 years; 50% female) with a mean follow-up of 5.9 years (range, 5.0 to 10.1 years) after primary TAA performed between October 2012 and December 2018. Patient-reported outcome measures (PROMs) included the 12-item Short Form Health Survey (SF-12) Physical Component Summary (PCS) and Mental Component Summary (MCS), Ankle Osteoarthritis Scale (AOS) for pain and disability, and visual analog scale (VAS) for pain. Radiographic measurements for range of motion, coronal and sagittal alignment, and implant subsidence were evaluated. The presence of periprosthetic radiolucency was determined using a 12-zone classification system. Adverse events were reported using the Canadian Orthopaedic Foot and Ankle Society (COFAS) Reoperation Coding System (CROCS).
The cohort had mean postoperative values of 41.5 for the SF-12 PCS, 54.9 for the SF-12 MCS, 2.3 for VAS pain, 19.1 for AOS pain, and 28.5 for AOS disability. The postoperative tibiotalar range of motion was 7.5° of dorsiflexion and 17.3° of plantar flexion. A total of 42 valgus ankles (mean coronal tibiotalar angle, 10.4°; range, 1.0° to 25.3°) and 44 varus ankles (mean, -9.1°; range, -1.0° to -25.0°) were corrected to neutral. Twenty-six ankles (20%) had 1 zone of radiolucency, and none of the ankles had >7 zones. There were 3 cases of cysts (2.3%) and 0 cases of subsidence, septic or aseptic loosening, or fibular nonunion. Adverse events occurred in 47 ankles (36.2%) at a mean of 26.7 months, with the most common reoperation being medial gutter debridement (22 ankles; 16.9%). There were 2 ankles (1.5%) with acute infection treated with debridement, antibiotics, and polyethylene exchange with metal component retention. Overall implant survivorship, defined as retention of the metal components, was 100% at the time of final follow-up.
The clinical and radiographic data in this study suggest that transfibular TAA is an effective and durable treatment option for end-stage ankle arthritis, with excellent mid-term implant survivorship. Periprosthetic radiolucency was limited and did not lead to implant subsidence or loosening. The most common reoperation was medial gutter debridement.
Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
虽然大多数全踝关节置换术(TAA)采用前路植入,但捷迈邦美小梁金属植入物的独特之处在于它采用经腓骨外侧入路。我们进行了迄今为止最大规模的中期研究,以分析经腓骨TAA在至少5年随访期的植入物生存率以及临床和影像学结果。
我们回顾性地识别并评估了2012年10月至2018年12月期间初次TAA术后平均随访5.9年(范围5.0至10.1年)的130例踝关节(122例患者;平均年龄60.8岁;50%为女性)。患者报告的结局指标(PROMs)包括12项简明健康调查问卷(SF-12)身体成分总结(PCS)和精神成分总结(MCS)、踝关节骨关节炎量表(AOS)的疼痛和功能障碍评分以及疼痛视觉模拟量表(VAS)。评估了活动范围、冠状面和矢状面排列以及植入物下沉的影像学测量值。使用12区分类系统确定假体周围透亮带的存在情况。使用加拿大足踝学会(COFAS)再次手术编码系统(CROCS)报告不良事件。
该队列患者术后SF-12 PCS平均为41.5、SF-12 MCS平均为54.9、VAS疼痛评分为2.3、AOS疼痛评分为19.1、AOS功能障碍评分为28.5。术后胫距关节活动范围为背屈7.5°和跖屈17.3°。共有42例外翻踝关节(平均冠状面胫距角10.4°;范围1.0°至25.3°)和44例内翻踝关节(平均-9.1°;范围-1.0°至-25.0°)被矫正至中立位。26例踝关节(20%)有1个透亮带区域,没有踝关节有超过7个区域。有3例囊肿(2.3%),没有下沉、感染性或无菌性松动或腓骨不愈合病例。47例踝关节(36.2%)发生不良事件,平均发生时间为26.7个月,最常见的再次手术是内侧沟清创术(22例踝关节;16.9%)。有2例踝关节(1.5%)发生急性感染,接受了清创、抗生素治疗以及保留金属部件的聚乙烯衬垫更换。在最后随访时,定义为金属部件保留的总体植入物生存率为100%。
本研究中的临床和影像学数据表明,经腓骨TAA是终末期踝关节关节炎的一种有效且持久的治疗选择,中期植入物生存率优异。假体周围透亮带有限,未导致植入物下沉或松动。最常见的再次手术是内侧沟清创术。
治疗性III级。有关证据水平的完整描述,请参阅作者须知。